OpenAlex
PricingAboutJobs
Log inGet started
Work

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

HTML

Year: 2017
Type: article
Study design: Clinical Trial
Source: The Journal of Clinical Pharmacology
DOI: 10.1002/jcph.950
Authors: Kei Sakamoto, Shunji Matsuki, Kyoko Matsuguma, Tatsuya Yoshihara, Naoki Uchida, Fumihiko Azuma, Muir Russell, Glen Hughes, Samantha Budd Haeberlein, Robert C. Alexander, Susanna Eketjäll, Alan R. Kugler
Institutions: Fukuoka Mirai Hospital, SHOWA Medical University, AstraZeneca (Japan), AstraZeneca (United Kingdom), AstraZeneca (United States), AstraZeneca (Sweden)
Language: English

Topic: Alzheimer's disease research and treatments
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: BACE1 inhibitors, Alzheimer's disease, pharmacokinetics, cerebrospinal fluid amyloid-beta, amyloid-beta 42, plasma amyloid-beta, disease-modifying therapy
SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca
OpenAlex ID: W2626081108
FWCI: 2.697
Cites: 30
Cited by: 67
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security